Swiss Biotech Firms Expand in China Amidst Supportive Policies
Swiss biotechnology firms like Versameb and Orexa are expanding into China, driven by supportive government policies and market potential; Versameb will invest up to $25 million in clinical trials, while Orexa will collaborate with Chinese research institutions, reflecting a broader trend of increas...
Swiss Biotech Firms Expand in China Amidst Supportive Policies
Swiss biotechnology firms like Versameb and Orexa are expanding into China, driven by supportive government policies and market potential; Versameb will invest up to $25 million in clinical trials, while Orexa will collaborate with Chinese research institutions, reflecting a broader trend of increas...
Progress
44% Bias Score
MAI Capital Management Highlights Pfizer, Airbus, and Domino's as Promising Non-Tech Stocks
Chris Grisanti of MAI Capital Management recommended Pfizer, Airbus, and Domino's as strong non-tech stock picks, citing Pfizer's low P/E ratio and dividend yield, Airbus's position in a growing industry, and Domino's recent positive performance.
MAI Capital Management Highlights Pfizer, Airbus, and Domino's as Promising Non-Tech Stocks
Chris Grisanti of MAI Capital Management recommended Pfizer, Airbus, and Domino's as strong non-tech stock picks, citing Pfizer's low P/E ratio and dividend yield, Airbus's position in a growing industry, and Domino's recent positive performance.
Progress
40% Bias Score
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Progress
60% Bias Score
AstraZeneca Profits Soar Despite UK Investment Cancellation and China Crisis
AstraZeneca's 2024 annual profits jumped 38% to $8.7bn due to strong sales of cancer, lung, and immunology treatments; however, the company cancelled a \£450m UK investment after disagreements over state support, and faces a crisis in China with detained executives and potential fines.
AstraZeneca Profits Soar Despite UK Investment Cancellation and China Crisis
AstraZeneca's 2024 annual profits jumped 38% to $8.7bn due to strong sales of cancer, lung, and immunology treatments; however, the company cancelled a \£450m UK investment after disagreements over state support, and faces a crisis in China with detained executives and potential fines.
Progress
40% Bias Score
Market Volatility: Delta Soars, Insurers Fall Amid Wildfires
In midday trading, Delta Air Lines shares surged 9% due to exceeding Q4 expectations, while Constellation Energy jumped 24% after announcing a $26.6 billion Calpine acquisition; however, several insurers dropped due to California wildfire losses, and other companies fell due to missed earnings or do...
Market Volatility: Delta Soars, Insurers Fall Amid Wildfires
In midday trading, Delta Air Lines shares surged 9% due to exceeding Q4 expectations, while Constellation Energy jumped 24% after announcing a $26.6 billion Calpine acquisition; however, several insurers dropped due to California wildfire losses, and other companies fell due to missed earnings or do...
Progress
44% Bias Score
BC 007 Fails Long Covid Trial, Subsidiary Files for Insolvency
A clinical trial for the Long Covid drug BC 007 showed negative results, leading to the insolvency of the drug's German subsidiary.
BC 007 Fails Long Covid Trial, Subsidiary Files for Insolvency
A clinical trial for the Long Covid drug BC 007 showed negative results, leading to the insolvency of the drug's German subsidiary.
Progress
0% Bias Score